Herpes drug Acyclovir does not reduce risk of HIV transmission, does slow HIV progression, study says

The drug acyclovir, which suppresses herpes simplex virus-2, does not reduce the risk of HIV transmission when taken by HIV-positive people who also have herpes, according to a study conducted by researchers at the University of Washington, United Press International reports.

According to United Press International, genital ulcers associated with HSV-2 are known to increase the risk of HIV transmission.

The study was conducted among 3,408 discordant couples, in which one member is HIV-positive and the other is not, at 14 sites in seven African countries: Botswana, Kenya, Rwanda, South Africa, Tanzania, Uganda and Zambia. The primary results of the study found that 41 new HIV cases occurred in the couples in which the HIV-positive member took acyclovir, compared with 43 new infections among the couples who did not take the drug. The results were not statistically significant, according to the researchers (United Press International, 5/13). However, the study did find that acyclovir can slow progression of HIV by 17% in HIV-positive people who also have HSV-2 and whose CD4+ T cell counts are too high to begin antiretroviral therapy.

"Although the primary outcome of reducing HIV transmission was not observed, the study yielded important information that will inform HIV prevention research in a number of ways," Connie Celum, a professor of global health and medicine at the University of Washington's Division of Allergy and Infectious Diseases, said. She added that the "findings will bear fruit for both the HIV prevention and vaccine fields for years to come."

The study, called the Partners in Prevention HSV/HIV Transmission Study, was funded by the Bill & Melinda Gates Foundation (University of Washington release, 5/8).

Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Lenacapavir: A breakthrough in long-acting HIV prevention for cisgender women